Parathyroid Adenoma

4

Review clinical trials related to Parathyroid Adenoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT

This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT

Participants needed: 100
Trial details
Phase: Phase 2, Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Andrei IagaruUpdated: Jun 24, 2026Locations: 1
Eligibility criteria

Suspected parathyroid adenoma (elevated serum calcium and inappropriately normal... [+6]

Less than 18 years old at the time of radiotracer administration [+2]

Status: Not yet recruiting

New Intraoperative Nerve Monitoring Device

This study is testing a new device developed to protect the recurrent laryngeal nerve, which is at risk of damage during thyroid and parathyroid surgeries.

Participants needed: 40
Trial details
Age: 18-70Biological sex: AllType: InterventionalSponsor: SB Istanbul Education and Research HospitalUpdated: Jul 17, 2025
Eligibility criteria

Age 18-70, diagnosis of benign/malignant thyroid disease, informed consent

History of previous nerve injury, concomitant neurological disorder

Status: Not yet recruiting

WHITE CAP: Intra-operative Parathyroid Tissue Sensor (PTS)-Guided Assessment of Parathyroid Viability and Surgical Decision-Making

Primary hyperparathyroidism is usually cured by removing the single over-active parathyroid adenoma. During surgery, however, surgeons often see a thin rim of normal parathyroid tissue that still "glows" under a near-infrared parathyroid tissue sensor (PTS). It is unclear whether keeping this tissue in place helps preserve hormone function or whether it leaves behind cells that could become over-active again. The WHITE CAP study will compare two common surgical choices: Preservation strategy - the surgeon removes only the adenoma and leaves the glowing rim of normal tissue untouched. En-bloc strategy - the surgeon removes the adenoma together with the glowing rim; if too little parathyroid tissue remains, a small fragment is transplanted into the forearm muscle. About 120 adult patients who have a single parathyroid adenoma will be randomly assigned (like tossing a coin) to one of the two strategies. All operations will use the same FDA-cleared PTS camera that shows the glands in real time without dye or radiation. The main question is whether preserving the normal rim lowers the rate of temporary low blood-calcium (numbness, tingling) during the first two days after surgery. The study will also check long-term results-blood calcium and parathyroid hormone (PTH) levels, symptoms, and any return of the disease-over two years. The PTS imaging itself is painless and adds only a few minutes to the operation. Risks are the same as for standard parathyroid surgery, and participants can withdraw at any time without affecting their usual care.

Participants needed: 120
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Fujian Medical UniversityUpdated: Jun 29, 2025Locations: 1
Eligibility criteria

Age 18 to 75 years, able to give informed consent. [+3]

Multiple endocrine neoplasia (MEN 1 or 2) or suspicion of multi-gland disease (>... [+5]

Status: Recruiting

PTeye in Parathyroid Adenoma

Identifying the parathyroids is compulsory for success of parathyroidectomy for parathyroid adenoma. Near-infrared autofluorescence devices have been proposed as useful intraoperative tools for the identification of parathyroid glands. The aim of the present study is to evaluate the correlation of PTeye autofluorescence device with biochemical data of parathyroid adenoma patients.

Participants needed: 50
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Aristotle University Of ThessalonikiUpdated: Apr 6, 2025Locations: 1
Eligibility criteria

Age >18 years old [+2]

Secondary and tertiary hyperparathyroidism [+3]